Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020
26 Octubre 2020 - 5:00AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host
a webcast and conference call on Thursday, November 5, 2020 at 5:00
p.m. EST to discuss its third quarter 2020 operating and financial
results.
The webcast will be accessible under "Events &
Presentations" in the Investors & Media page of the Company’s
website at acceleronpharma.com. Individuals can participate in the
conference call by dialing 877-312-5848 (domestic) or 253-237-1155
(international) and referring to the “Acceleron Third Quarter 2020
Earnings Call.”
The archived webcast will be available for replay on the
Acceleron website approximately two hours after the event.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its commercialization, research, and
development efforts in hematologic and pulmonary diseases. In
hematology, REBLOZYL® (luspatercept-aamt) is the first and only
erythroid maturation agent approved in the United States, Europe,
and Canada for the treatment of anemia in certain blood disorders.
REBLOZYL is part of a global collaboration partnership with Bristol
Myers Squibb. The Companies co-promote REBLOZYL in North America
and are also developing luspatercept for the treatment of anemia in
patient populations of MDS, beta-thalassemia, and myelofibrosis. In
pulmonary, Acceleron is developing sotatercept for the treatment of
pulmonary arterial hypertension (PAH), having recently presented
positive topline results of the PULSAR Phase 2 trial. The Company
is currently planning multiple Phase 3 trials with the potential to
support its long-term vision of establishing sotatercept as a
backbone therapy for patients with PAH at all stages of the
disease.
For more information, please visit acceleronpharma.com. Follow
Acceleron on social media: @AcceleronPharma and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201026005095/en/
Investors: Jamie Bernard, IRC, (617) 649-9650 Associate
Director, Investor Relations
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. Artículos de Noticias